-
Genome Storage for $25
Technology Review | Google Genomics says it is storing at least 3,500 genomes at the rate of $25 per genome per year. The analytics cost extra.
Nov 6, 2014
-
What a Big Data Buy Could Mean
ReadWrite | One acquisition in the Big Data space could change everything, one analyst predicts, pointing out that if Oracle or Cisco were to snap up one of the Big Data start-ups the collateral damage would be severe.
Nov 6, 2014
-
Google to Cover Foundation Medicine Tests for All Employees
BetaBoston | Foundation Medicine, the largest and most visible provider of broad genetic tests for personalized cancer therapy, announced this week that Google will pay for its tests for anyone covered under Google health plans.
Nov 6, 2014
-
AstraZeneca Buys Definiens in Bid for Ground-Up Co-Diagnostics Pipeline
Bio-IT World News Brief | AstraZeneca announced that it has acquired Definiens, a diagnostics company specializing in image analysis software, as part of a strategy to refine its immuno-oncology programs.
Nov 5, 2014
-
October News and Product Briefs
Bio-IT World | News and product releases from around the industry, including the GIANT Consortium's record-breaking GWAS, a new organ-on-a-chip company, and plenty of announcements from the annual meeting of the American Society for Human Genetics.
Nov 4, 2014
-
NCI Awards Contracts for Cancer Genomics Cloud Pilots
Bio-IT World News Brief | The National Cancer Institute has chosen two academic institutes and one private company to develop separate compute infrastructures for the analysis of cloud-hosted genomics data generated by large, public projects.
Nov 3, 2014
-
Jonathan Rothberg Pursues Mobile Ultrasound
MIT Technology Review | Jonathan Rothberg, founder of both 454 Life Sciences and Ion Torrent, is touting a new startup from his 4Combinator tech incubator that is developing a low-cost ultrasound device to plug into a smartphone.
Nov 3, 2014
-
In a Restless Preclinical Testing Market, Organs-on-Chips Company MIMETAS Is in Expansion Mode
Bio-IT World | Dutch startup MIMETAS, whose microfluidics technology forms a platform for three-dimensional, multi-cell-type tissue cultures, is securing new funding and partnerships as it expands its line of drug screening models.
Oct 31, 2014


